Hydroxychloroquine failed to prevent COVID-19 in adults, 800-person study finds

Hydroxychloroquine is no more effective than a vitamin placebo in preventing COVID-19 in individuals who have been exposed to the disease, according to a study released June 3 from the Minneapolis-based University of Minnesota Medical School.

Advertisement

The study, which began in mid-March, is the first to test the malaria drug as a preventative measure. Researchers enrolled 800 people in the U.S. and Canada, most of which were front-line healthcare workers, who had been exposed to someone with COVID-19. 

Participants received either hydroxychloroquine or a vitamin placebo for five days and were then monitored for two weeks. The study was double-blinded, so neither the participants nor the researchers knew which medication was being received.

More articles on pharmacy:
Eli Lilly testing COVID-19 drug derived from survivor blood
Researchers testing several heart, anti-platelet drugs for COVID-19 patients
4 pharmacy leaders on mitigating drug shortages during a pandemic

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.